Patents by Inventor Ursula-Friederike Habenicht

Ursula-Friederike Habenicht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060142257
    Abstract: A formulation for male contraception comprising a progestin possessing both estrogenic and androgenic properties is remarkably effective for spermatogenesis suppression in males. The progestin Norethisterone (NET), particularly its derivatives Norethisterone acetate and Norethisterone enanthate in sufficient doses induce oligozoospermia or azoospermia in males. Formulations further comprising an androgen, such as a testosterone derivative such as a testosterone ester, particularly testosterone undecanoate, are especially effective male contraceptive formulations.
    Type: Application
    Filed: February 17, 2006
    Publication date: June 29, 2006
    Inventors: Eberhard Nieschlag, Axel Kamischke, Michael Oettel, Alexander Ruebig, Ekkerhard Schillinger, Ursula-Friederike Habenicht
  • Patent number: 7025979
    Abstract: A formulation for male contraception comprising a progestin possessing both estrogenic and androgenic properties is remarkably effective for spermatogenesis suppression in males. The progestin Norethisterone (NET), particularly its derivatives Norethisterone acetate and Norethisterone enanthate in sufficient doses induce oligozoospermia or azoospermia in males. Formulations further comprising an androgen, such as a testosterone derivative such as a testosterone ester, particularly testosterone undecanoate, are especially effective male contraceptive formulations.
    Type: Grant
    Filed: January 19, 2001
    Date of Patent: April 11, 2006
    Assignee: Schering AG
    Inventors: Eberhard Nieschlag, Axel Kamischke, Michael Oettel, Alexander Ruebig, Ekkerhard Schillinger, Ursula-Friederike Habenicht
  • Patent number: 6344442
    Abstract: The present invention relates to the use of peptides which are derived from zona pellucida proteins and are used for contraception, and pharmaceutical formulations which contain the peptides without the peptides having an immunogenic effect.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: February 5, 2002
    Assignee: Schering Aktiengesellschaft
    Inventors: Ursula-Friederike Habenicht, Alessandro Lobbia
  • Publication number: 20020004479
    Abstract: The present invention relates to the use of peptides which are derived from zona pellucida proteins and are used for contraception, and pharmaceutical formulations which contain said peptides without said peptides having an immunogenic effect.
    Type: Application
    Filed: May 3, 1999
    Publication date: January 10, 2002
    Inventors: URSULA-FRIEDERIKE HABENICHT, ALESSANDRO LOBBIA
  • Publication number: 20010056086
    Abstract: This invention describes the use of antiestrogens (aromatase inhibitors, estrogen receptor antagonists) for the production of pharmaceutical agents for male birth control.
    Type: Application
    Filed: August 6, 1998
    Publication date: December 27, 2001
    Inventor: URSULA-FRIEDERIKE HABENICHT
  • Patent number: 5861389
    Abstract: Male menopause is characterized by significant decreases in serum levels of bioavailable androgens. The administration of aromatase inhibitors to men experiencing male menopause can remedy the relative androgen deficiency in men while at the same time approximating the physiological hormonal ratio of androgens to estrogens.
    Type: Grant
    Filed: June 13, 1997
    Date of Patent: January 19, 1999
    Assignee: Schering Aktiengesellschaft
    Inventors: Albert Radlmaier, Ursula-Friederike Habenicht, Friedmund Neumann